The Effect of Early Enteral Nutrition Feeding Process Assisted by Gastrointestinal Ultrasonography

January 27, 2026 updated by: Chinese Medical Association

The Effect of Early Enteral Nutrition Feeding Process Assisted by Gastrointestinal Ultrasonography in Critically Ill Patients

In critical ill patients, feeding protocol is one of the important factor which determines the successful implementation of enteral nutrition(EN). Acute gastrointestinal injury(AGI) affects feeding tolerance, which greatly determines the successful implementation of feeding protocol. In our previously study, we found that transabdominal intestinal sonography is helpful to diagnosis AGI. Thus in this study ,we apply transabdominal gastrointestinal sonography to feeding protocol, to assess the feasibility of gastrointestinal sonography assisted enteral nutrition and its impact on critical ill patients.

Study Overview

Detailed Description

Patients meeting inclusion and exclusion criteria were randomly assigned to the intervention group and control group. During the first week of initiation of nutrition, enteral nutrition was conducted according to different procedures to observe the impact of different feeding procedures on clinical indicators

Study Type

Interventional

Enrollment (Actual)

294

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Jiangsu
      • Nanjing, Jiangsu, China, 210000
        • Nanjing Drum Tower Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • The age is not less than 18 years
  • within 24 hours after entering ICU
  • Acute Physiology and Chronic Health Evaluation II (APACHE II) score > 8
  • the estimated length of stay in ICU is more than 3 days
  • informed consent

Exclusion Criteria:

  • The normal anatomy of stomach, small intestine or the right colon was significantly changed (Gastrectomy, esophagectomy, pancreaticoduodenectomy, gastrointestinal bypass surgery, the presence of short bowel syndrome,etc.)
  • Uncontrolled gastrointestinal bleeding
  • Uncontrolled intestinal obstruction
  • Uncontrolled mesenteric vascular disease
  • Pregnancy
  • breastfeeding
  • Received enteral nutrition or parenteral nutrition within 24 hours prior to ICU admission
  • Predict death within 48 hours after ICU admission
  • Enrolled in this study before.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: control group
Implement nutrition therapy according to existing feeding procedures
Experimental: intervention group
Implement nutrition therapy according a procedure assisted by gastrointestinal ultrasound
Once the critical ill patients is stable, enteral nutrition was initiated following a procedure assisted by gastrointestinal ultrasound.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Target-reaching rate through enteral route
Time Frame: Within first week
percentage of participants who reach target calorie through enteral route
Within first week

Secondary Outcome Measures

Outcome Measure
Time Frame
The incidence of feeding intolerance
Time Frame: Within first week
Within first week
The application of parenteral nutrition
Time Frame: Within first week
Within first week
The application of prokinetic drugs
Time Frame: Within first week
Within first week
The ues of vasoactive drugs
Time Frame: Within first week
Within first week
Mechanical ventilation
Time Frame: Within first week
Within first week
Continuous renal replacement
Time Frame: Within first week
Within first week
The CRP level
Time Frame: Day0/1/3/5/7
Day0/1/3/5/7
Mortality
Time Frame: Day28、Day60、during hospitalization
Day28、Day60、during hospitalization
ICU length of stay
Time Frame: During ICU stay
During ICU stay
Length of hospital stay
Time Frame: During hospital stay
During hospital stay
Platelet count
Time Frame: Day0,1,3,5,7
Day0,1,3,5,7
Total bilirubin
Time Frame: Day0,1,3,5,7
Day0,1,3,5,7
Serum creatinine
Time Frame: Day0,1,3,5,7
Day0,1,3,5,7

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: WenKui Yu, Professor, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2022

Primary Completion (Actual)

October 1, 2023

Study Completion (Actual)

October 1, 2023

Study Registration Dates

First Submitted

April 28, 2022

First Submitted That Met QC Criteria

May 13, 2022

First Posted (Actual)

May 18, 2022

Study Record Updates

Last Update Posted (Actual)

January 28, 2026

Last Update Submitted That Met QC Criteria

January 27, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2022-050-02

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe